Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development

On Thursday, Evotec SE (NASDAQ:EVO) entered a technology development partnership with Novo Nordisk A/S (NYSE:NVO) in cell therapy.

Evotec and Novo Nordisk have significant expertise and a strategic focus on supporting stem cell-based therapies.

Also Read: German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount.

To provide next-generation off-the-shelf cell therapy products for clinical development and possible commercialization, the companies will collaborate on developing advanced technologies in support thereof.

Under the collaboration agreement, Novo Nordisk will fund technology development ...